New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
14:00 EDTHALO, BAXBaxter, Halozyme announce favorable FDA panel recommendation on HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the Blood Products Advisory Committee of the FDA voted 15-1 that HyQvia, Baxter’s investigational subcutaneous treatment for patients with primary immunodeficiency, has a favorable risk/benefit profile. ''We are hopeful that the positive support for HyQvia is the next step toward providing a new treatment option for patients with primary immunodeficiency in the United States. We look forward to working closely with the FDA as it completes its review,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. HyQvia was approved in Europe in 2013 for adults with primary immunodeficiency syndromes and myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. HyQvia is a product consisting of human normal immunoglobulin and recombinant human hyaluronidase, licensed from Halozyme.
News For BAX;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2015
08:04 EDTBAXBaxter announces FDA clearance for AMIA APD system with Sharesource platform
Subscribe for More Information
October 7, 2015
07:36 EDTBAXInfectious Diseases Society of America to hold a conference
Subscribe for More Information
September 30, 2015
09:29 EDTBAXBaxter agrees to add Third Point representative to board
Subscribe for More Information
09:24 EDTBAXThird Point reaches standstill pact with Baxter, reports 9.9% stake
09:02 EDTBAXBaxter appoints Munib Islam to board; announces agreement with Third Point
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use